Sanofi (SNY) has released an update.
Sanofi has partnered with South African biopharmaceutical company Biovac to produce inactivated polio vaccines (IPV) in Africa, marking Biovac as the continent’s first producer of IPV. This collaboration aims to support local vaccine production for over 40 African countries and aligns with the Africa CDC’s goal of locally producing 60% of vaccines by 2040. The partnership is a strategic move to fortify polio vaccination programs, which were affected during the COVID-19 pandemic, and to sustain efforts toward global polio eradication.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
